Examples: breast cancer, NCT03147287, pd-l1

Top 100 results for: "ovarian cancer"

Not Enrolling

Women's Activity and Lifestyle study (WALC)

Trial Description: Despite an increase in longevity, surviving ovarian cancer often brings an array of unpleasant side effects and compromises in QOL. Our proposed trial will be the first study to test whether exercise compared with attention control has a beneficial impact on quality of life, fitness and surrogate markers of ovarian cancer. Our trial could suggest a unique and important role for exercise in ovarian cancer care given that physical and functional aspects of QOL are often the most compromised in ovarian cancer patients.

  • Conditions: ovarian cancer
  • Phase: Feasibility / Pilot
  • Trial ID: NCT02107066
  • Protocol ID: 11-201

Not Enrolling

Stand up to Cancer: WISP Trial (Women Choosing Surgical Prevention)

Trial Description: This phase II trial studies how well surgery works in preventing ovarian cancer in patients with genetic mutations at risk of ovarian cancer. Risk reducing salpingo oophorectomy (RRSO) is surgery to remove the fallopian tubes and ovaries at the same time. Interval salpingectomy with delayed oophorectomy (ISDO) is surgery to remove the fallopian tubes. It is not known whether ISDO works better than RRSO at lowering risk of ovarian cancer and improving the sexual function and psychosocial well-being in patients with genetic mutation.

  • Conditions: deleterious bard1 gene mutation, deleterious brca1 gene mutation, deleterious brca2 gene mutation, deleterious brip1 gene mutation, deleterious epcam gene mutation, deleterious mlh1 gene mutation, deleterious msh2 gene mutation, deleterious msh6 gene mutation, deleterious palb2 gene mutation, deleterious pms2 gene mutation, deleterious rad51c gene mutation, deleterious rad51d gene mutation, hereditary breast and ovarian cancer syndrome, premenopausal
  • Phase: Not Applicable
  • Trial ID: NCT02760849
  • Protocol ID: 16-389

Not Enrolling

PHASE 2 MULTICOHORT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NOVEL TREATMENT COMBINATIONS IN PATIENTS WITH RECURRENT OVARIAN CANCER

Trial Description: This study will evaluate the efficacy and safety of niraparib and novel treatment combinations of niraparib as described within each cohort-specific supplement in participants with ovarian, fallopian tube, or primary peritoneal cancer. Cohort A (single arm) includes participants with recurrent ovarian cancer. Cohort B will not be initiated. Cohort C (randomized-2 arms) includes participants with newly diagnosed ovarian cancer.

  • Conditions: ovarian neoplasms
  • Phase: I/II
  • Trial ID: NCT03574779
  • Protocol ID: 18-303

Not Enrolling

A Randomized, Double-Blind, Phase 3 Comparison Of Platinum-Based Therapy With TSR-042 And Niraparib Versus Standard Of Care Platinum-Based Therapy As First-Line Treatment Of Stage III Or IV Nonmucinous Epithelial Ovarian Cancer

Trial Description: Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular endothelial growth factor (VEGF) receptor, programmed death receptor ligands 1 (PD-L1) expression, and deoxyribonucleic acid (DNA) damage in ovarian tumors provide several targets for treatment and maintenance of disease response. Given the unmet medical need of participants with advanced or metastatic ovarian cancer, this study design will enable investigators to provide participants with current SOC for ovarian cancer for the duration

  • Conditions: ovarian cancer, ovarian neoplasms
  • Phase: III
  • Trial ID: NCT03602859
  • Protocol ID: 18-486

Not Enrolling

A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

Trial Description: The purpose of this study is to evaluate the efficacy and safety of prexasertib in women with platinum-resistant or refractory recurrent ovarian cancer.

  • Conditions: ovarian cancer
  • Phase: II
  • Trial ID: NCT03414047
  • Protocol ID: 18-077

Not Enrolling

Open-label, Phase I study of NeoVax with Nivolumab in Patients with Ovarian Cancer

Trial Description: This research study is evaluating a new type of vaccine called "Personalized NeoAntigen Cancer Vaccine" in combination with Nivolumab (Opdivo®) for ovarian cancer.

  • Conditions: ovarian cancer
  • Phase: I
  • Trial ID: NCT04024878
  • Protocol ID: 18-318

Enrolling

Combination ATR and PARP Inhibitor (CAPRI) trial with AZD6738 and olaparib in recurrent ovarian cancer.

Trial Description: Investigational agent, AZD6738 will be given in combination with Olaparib to women with recurrent ovarian cancer (platinum-sensitive or platinum-resistant). This study will determine if using Olaparib in combination with AZD6738 is safe and tolerable and also determine the objective response rate and progression free survival of combination of AZD6738 and Olaparib in women with recurrent ovarian cancer in distinct platinum-sensitive and platinum-resistant cohorts.

  • Conditions: high grade serous carcinoma
  • Phase: I/II
  • Trial ID: NCT03462342
  • Protocol ID: 20-320

Enrolling

Living WELL: A web-based program to improve quality of life in rural and urban ovarian cancer survivors

Trial Description: The purpose of this study is to determine the efficacy of a group-based and web-delivered psychosocial intervention for ovarian cancer survivors (Mindful Living [ML]) compared to a health promotion condition (Healthy Lifestyles [HL]) in increasing health related quality of life (HRQOL) and decreasing perceived stress, depressive mood (primary aims), anxiety, and fatigue (secondary aims) across a 12-month period.

  • Conditions: ovarian cancer
  • Phase: Not Applicable
  • Trial ID: NCT04533763
  • Protocol ID: 21-745

Not Enrolling

REVITALIZE: A Telehealth Intervention for Women with Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue

Trial Description: This study is testing whether a 6 week skills-based telehealth intervention can help ovarian cancer patients experiencing PARP inhibitor-related fatigue reduce the impact of fatigue on their daily life and activities.

  • Conditions: coping behavior, coping skills, fatigue, ovarian cancer
  • Phase: Feasibility / Pilot
  • Trial ID: NCT04525183
  • Protocol ID: 20-285

Not Enrolling

Stepping into Survivorship

Trial Description: This research study will test whether using wearable fitness trackers with a social incentive, delivered through a game-based mobile health intervention, increases physical activity and quality of life in ovarian cancer survivors.

  • Conditions: ovarian cancer
  • Phase: Not Applicable
  • Trial ID: NCT03364673
  • Protocol ID: 17-361

Enrolling

EPIK-O: A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistan

Trial Description: The objective of this study is to assess the efficacy and safety of the combination of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian cancer, with no germline BRCA mutation detected.

  • Conditions: ovarian cancer
  • Phase: III
  • Trial ID: NCT04729387
  • Protocol ID: 21-368

Not Enrolling

A PHASE 1B/2 RANDOMIZED, CONTROLLED STUDY OF AVB-S6-500 IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN OR PACLITAXEL IN PATIENTS WITH PLATINUM-RESISTANT RECURRENT OVARIAN CANCER

Trial Description: This is a Phase 1b/2 study of AVB-S6-500 in combination with pegylated liposomal doxorubicin (PLD) or paclitaxel (Pac) in patients with platinum resistant recurrent ovarian cancer. The phase 1b portion of the study is open label and patients will receive either AVB-S6-500+PLD or AVB-S6-500+ Pac. The Phase 2 portion of the study is randomized, double-blind, placebo-controlled study to compare efficacy and tolerability of AVB-S6-500 in combination with PLD or Pac versus placebo plus PLD or Pac.

  • Conditions: ovarian cancer
  • Phase: I/II
  • Trial ID: NCT03639246
  • Protocol ID: 18-554

Enrolling

Exercise as a Preventive Agent to Combat Immobility in Patients with Ovarian or Endometrial Cancers Receiving Chemotherapy

Trial Description: The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs), lessen chemotherapy-induced peripheral neuropathy (CIPN; numbness or tingling in the hands or feet), and if there is any effect on inflammatory blood markers (the level of a certain marker in the blood that is associated with inflammation; redness and swelling).

  • Conditions: endometrial cancer, endometrial cancer stage, ovarian cancer, ovarian cancer stage 3, ovarian cancer stage iii, ovarian cancer stage iv, ovarian carcinoma
  • Phase: Feasibility / Pilot
  • Trial ID: NCT04997096
  • Protocol ID: 21-299

Not Enrolling

A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial Cancer, Epithelial Ovarian Cancer, or Carcinosarcoma

Trial Description: A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial Cancer, Epithelial Ovarian Cancer, or Carcinosarcoma

  • Conditions: carcinosarcoma, endometrial cancer, ovarian cancer, uterine cancer
  • Phase: II
  • Trial ID: NCT03395080
  • Protocol ID: 17-499

Not Enrolling

Phase 2, prospective open label, single arm study to investigate anti-tumor effect and tolerability of 2X-121 in patients with advanced ovarian cancer selected by the 2X-121 DRP®. (2X-1002 Main study) and (2X-1000 Pre-screening study)

Trial Description: This study is to be performed as an open label, multicenter, single arm study of 2X-121 to evaluate anti-tumor efficacy of 2X-121 as single agent therapy in a 28-days cycle in advanced ovarian cancer patients. 2X-121 will be supplied for oral administration once daily as 600 mg (3 x 200 mg) capsules in a 28 days cycle. Patients with predicted high likelihood of responding to the drug (2X-121) using drug response prediction (DRP®), will be included in the study.

  • Conditions: advanced ovarian cancer
  • Phase: II
  • Trial ID: NCT03878849
  • Protocol ID: 18-633

Enrolling

A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)

Trial Description: This is a randomized, double-blind Phase 3 study to compare the efficacy and safety of batiraxcept (AVB-S6-500) in combination with paclitaxel (PAC) versus placebo in combination with PAC in patients with platinum resistant recurrent ovarian cancer.

  • Conditions: platinum-resistant ovarian cancer
  • Phase: III
  • Trial ID: NCT04729608
  • Protocol ID: 21-237

Enrolling

A Phase II Trial of Pembrolizumab and Lenvatinib in Patients with Recurrent or Persistent Clear Cell Carcinoma of the Ovary

Trial Description: This research study is being done to test the efficacy and safety of combining the study drugs pembrolizumab and lenvatinib in patients with clear cell ovarian cancer. The names of the study drugs involved in this study are: - Lenvatinib - Pembrolizumab

  • Conditions: gynecologic cancer, ovarian clear cell carcinoma
  • Phase: II
  • Trial ID: NCT05296512
  • Protocol ID: 21-739

Not Enrolling

A Multicenter, Open-Label, Parallel, Phase 2a Study of PLX2853 Monotherapy in Advanced Gynecological Malignancies with a Known ARID1A Mutation and Phase 1b/2a Study of PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer

Trial Description: The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in Advanced Gynecological Malignancies with a Known ARID1A Mutation and PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer.

  • Conditions: epithelial ovarian cancer, gynecologic neoplasms
  • Phase: I/II
  • Trial ID: NCT04493619
  • Protocol ID: 20-257

Enrolling

Phase 1 Trial of Gemcitabine Combined with the BAY 1895344 ATR Inhibitor with Expansion Cohorts in Advanced Pancreatic and Ovarian Cancer

Trial Description: This phase I trial identifies the best dose, possible benefits and/or side effects of gemcitabine in combination with BAY 1895344 in treating patients with pancreatic, ovarian, and other solid tumors that have spread to other places in the body (advanced). Gemcitabine is a chemotherapy drug that blocks the cell from making DNA and may kill tumor cells. BAY 1895344 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine and BAY 1895344 in combination may shrink or stabilize cancer.

  • Conditions: advanced fallopian tube carcinoma, advanced malignant solid neoplasm, advanced ovarian carcinoma, advanced pancreatic adenocarcinoma, advanced primary peritoneal carcinoma, fallopian tube high grade serous adenocarcinoma, metastatic pancreatic adenocarcinoma, ovarian high grade serous adenocarcinoma, platinum-resistant fallopian tube carcinoma, platinum-resistant ovarian carcinoma, platinum-resistant primary peritoneal carcinoma, primary peritoneal high grade serous adenocarcinoma, stage ii pancreatic cancer ajcc v8, stage iii fallopian tube cancer ajcc v8, stage iii ovarian cancer ajcc v8, stage iii pancreatic cancer ajcc v8, stage iii primary peritoneal cancer ajcc v8, stage iv fallopian tube cancer ajcc v8, stage iv ovarian cancer ajcc v8, stage iv pancreatic cancer ajcc v8, stage iv primary peritoneal cancer ajcc v8, unresectable pancreatic adenocarcinoma
  • Phase: I
  • Trial ID: NCT04616534
  • Protocol ID: 21-149

Enrolling

A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Recurrent Ovarian Cancer

Trial Description: Primary Objectives In the Dose Escalation Phase: • To assess the safety and pharmacokinetics (PK) in order to determine a maximally tolerated dose (MTD) or recommended phase 2 dose (RP2D) of REGN4018 as monotherapy and in combination with cemiplimab. In the Dose Expansion Phase: • To assess the preliminary efficacy of REGN4018 as monotherapy and in combination with cemiplimab, (separately by cohort) as determined by the objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Secondary Objectives In the Dose Escalation Phase: • To assess

  • Conditions: recurrent fallopian tube cancer, recurrent ovarian cancer, recurrent primary peritoneal cancer
  • Phase: I/II
  • Trial ID: NCT03564340
  • Protocol ID: 18-227

Not Enrolling

A PHASE 2 OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE COMBINATION OF NIRAPARIB AND TSR-042 IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER (MOONSTONE)

Trial Description: This is an open-label, single-arm Phase 2 study to evaluate the efficacy and safety of combination of niraparib and dostarlimab (TSR-042) in participants with advanced, relapsed, high-grade ovarian, fallopian tube, endometrioid, clear cell ovarian or primary peritoneal cancer without known breast cancer susceptibility gene (BRCA) mutation who have platinum-resistant disease and who have also been previously treated with bevacizumab.

  • Conditions: ovarian neoplasms
  • Phase: II
  • Trial ID: NCT03955471
  • Protocol ID: 19-408

Not Enrolling

A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

Trial Description: Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast cancer, recurrent platinum sensitive ovarian cancer, urothelial cancer (UC), and castration resistant prostate cancer (CRPC).

  • Conditions: avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors
  • Phase: I/II
  • Trial ID: NCT03330405
  • Protocol ID: 17-687

Enrolling

A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum-Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)

Trial Description: This phase I trial studies the side effects and best dose of peposertib when given together with pegylated liposomal doxorubicin hydrochloride in treating patients with high or low grade ovarian cancer that has come back (recurrent). Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving peposertib and pegylated liposomal doxorubicin hydrochloride may work better in treating patients with ovarian cancer compared to pegylated liposomal doxorubicin hydrochloride alone.

  • Conditions: fallopian tube carcinosarcoma, fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube high grade serous adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube transitional cell carcinoma, fallopian tube undifferentiated carcinoma, figo grade 1 endometrial endometrioid adenocarcinoma, figo grade 2 endometrial endometrioid adenocarcinoma, high grade endometrial endometrioid adenocarcinoma, ovarian high grade serous adenocarcinoma, ovarian seromucinous carcinoma, ovarian undifferentiated carcinoma, platinum-sensitive ovarian carcinoma, primary peritoneal carcinosarcoma, primary peritoneal high grade serous adenocarcinoma, primary peritoneal transitional cell carcinoma, primary peritoneal undifferentiated carcinoma, recurrent fallopian tube carcinoma, recurrent low grade fallopian tube serous adenocarcinoma, recurrent ovarian carcinoma, recurrent ovarian carcinosarcoma, recurrent ovarian clear cell adenocarcinoma, recurrent ovarian endometrioid adenocarcinoma, recurrent ovarian low grade serous adenocarcinoma, recurrent ovarian mucinous adenocarcinoma, recurrent ovarian transitional cell carcinoma, recurrent primary peritoneal carcinoma, recurrent primary peritoneal low grade serous adenocarcinoma
  • Phase: I
  • Trial ID: NCT04092270
  • Protocol ID: 20-271

Not Enrolling

A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b

Trial Description: First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks. Patients with tumor types likely to express NaPi2b were enrolled in dose escalation. Patients with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma subtype) were enrolled in the expansion segment of this study. Patients with platinum-resistant, high-grade serous ovarian cancer are being enrolled in the UPLIFT segment of this study. In addition to safety assessments, the pharmacokinetics of the drug will be assessed along with ADC activity. A QTc sub-study has been added for the UPLIFT cohort for a sub-set of sites.

  • Conditions: non small cell lung cancer metastatic, platinum resistant ovarian cancer
  • Phase: I
  • Trial ID: NCT03319628
  • Protocol ID: 17-621

Enrolling

Pilot study of an implantable microdevice for evaluating drug responses in situ in ovarian, fallopian tube, and peritoneal cancer

Trial Description: This pilot study will assess the feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in ovarian, fallopian tube, and primary peritoneal cancer. The name of the study intervention involved in this study is: -implantable microdevice

  • Conditions: fallopian tube cancer, fallopian tube cancer stage iii, fallopian tube cancer stage iv, ovarian cancer, ovarian cancer stage iii, ovarian cancer stage iv, peritoneal cancer
  • Phase: Feasibility / Pilot
  • Trial ID: NCT04701645
  • Protocol ID: 20-357

Not Enrolling

ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Trial Description: This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.

  • Conditions: complete response, epithelial ovarian cancer, fallopian tube cancer, figo stage iii-iv, newly diagnosed, partial response, primary peritoneal
  • Phase: III
  • Trial ID: NCT03522246
  • Protocol ID: 18-481

Not Enrolling

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2-Expressing Tumors (DESTINY-PanTumor02)

Trial Description: This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors. This study will enroll 7 tumor-specific cohorts: urothelial bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and rare tumors. Study hypothesis: Trastuzumab deruxtecan will show meaningful clinical activity and a favorable risk benefit profile in selected HER2-expressing solid tumors.

  • Conditions: bladder cancer biliary tract cancer cervical cancer endometrial cancer ovarian cancer pancreatic cancer rare tumors
  • Phase: II
  • Trial ID: NCT04482309
  • Protocol ID: 21-051

Enrolling

A phase II study with a safety lead-in of nivolumab in combination with bevacizumab or in combination with bevacizumab and rucaparib for the treatment of relapsed epithelial ovarian, fallopian tube or peritoneal cancer

Trial Description: This research study is evaluating three drugs called Nivolumab, Bevacizumab, and Rucaparib as a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal Cancer.

  • Conditions: fallopian tube cancer, ovarian cancer, peritoneal cancer
  • Phase: II
  • Trial ID: NCT02873962
  • Protocol ID: 16-263

Not Enrolling

A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors

Trial Description: This study consists of two parts. Part 1 is a dose-escalation/safety evaluation to provisionally identify a dose and regimen of SY-1365 for further evaluation in Part 2. Following the identification of a recommended dose and regimen from Part 1, the study entered Part 2 to further evaluate safety and the antitumor activity of SY-1365 in patients with select solid tumors, and to confirm target engagement and downstream pathway impact in patients with any solid tumor histology

  • Conditions: advanced solid tumors, breast cancer, ovarian cancer
  • Phase: I
  • Trial ID: NCT03134638
  • Protocol ID: 17-236

Not Enrolling

A phase I dose finding study of oral LXH254 in adult patients with advanced solid tumors harboring MAPK pathway alterations

Trial Description: A Phase I Study of LXH254 in Patients With Advanced Solid Tumors That Harbor MAPK Pathway Alterations

  • Conditions: melanoma, nsclc, other solid tumors, ovarian cancer
  • Phase: I
  • Trial ID: NCT02607813
  • Protocol ID: 18-108

Not Enrolling

A phase 1 study of the CDK4/6 inhibitor ribociclib (LEE011) in combination with the PD-1 inhibitor PDR001 in patients with metastatic hormone receptor-positive breast cancer and metastatic ovarian cancer

Trial Description: This clinical trial is studying the drug Ribociclib (LEE011) in combination with an immunotherapy drug called PDR001 (a therapy that uses the body's own immune system to control cancer) as a possible treatment for metastatic hormone-receptor-positive (HR+), HER2-negative breast cancer (in combination with fulvestrant) or metastatic epithelial ovarian cancer. The names of the medications involved in this study are: - Ribociclib (LEE011) - PDR001 - Fulvestrant

  • Conditions: her2-negative breast cancer, metastatic epithelial ovarian cancer, metastatic hormone-receptor-positive (hr+) breast cancer
  • Phase: I
  • Trial ID: NCT03294694
  • Protocol ID: 17-285

Enrolling

OPTimizing Treatment Focused Genetic Testing IN Advanced Cancer- OPT-IN

Trial Description: This two-part randomized controlled trial aims to evaluate the impact of pre-test video education as compared to pre-test Chatbot education

  • Conditions: breast cancer, ovarian cancer, pancreatic cancer, prostate cancer
  • Phase: Not Applicable
  • Trial ID: NCT04066361
  • Protocol ID: 19-068

Not Enrolling

SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

Trial Description: This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with platinum-resistant high-grade serous epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of Folate Receptor-Alpha (FRα). Patients will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. All patients will receive single-agent MIRV at 6 mg/kg adjusted ideal body weight administered on Day 1 of every 3-week cycle.

  • Conditions: epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer
  • Phase: III
  • Trial ID: NCT04296890
  • Protocol ID: 20-096

Enrolling

PHASE 1/2 STUDY OF REGN5668 (MUC16 X CD28, A COSTIMULATORY BISPECFIC) ADMINISTERED IN COMBINATION WITH CEMIPLIMAB OR REGN4018 (MUC16 X CD3)

Trial Description: The primary objectives of the study are: In the Dose Escalation Phase: - To assess the safety, tolerability, and pharmacokinetics (PK) of REGN5668 alone and in separate combinations with cemiplimab or REGN4018, in order to determine a maximally tolerated dose(s) (MTD) or recommended phase 2 dose(s) (RP2D) of these combinations In the Dose Expansion Phase: - To assess the preliminary efficacy of REGN5668 in combination with cemiplimab or REGN4018, (separately by cohort and combination) as determined by the objective response rate (ORR) by Response Evaluation Criteria in Solid

  • Conditions: fallopian tube cancer, ovarian cancer, primary peritoneal cancer
  • Phase: I/II
  • Trial ID: NCT04590326
  • Protocol ID: 20-405

Enrolling

A PHASE 2 TRIAL OF NIROGACESTAT IN PATIENTS WITH RECURRENT OVARIAN GRANULOSA CELL TUMORS

Trial Description: This phase 2 clinical trial will study the effectiveness of nirogacestat in ovarian granulosa cell tumors (OvGCTs). Nirogacestat is a gamma secretase inhibitor (GSI) which is hypothesized to decrease the growth and activity of ovarian granulosa tumors.

  • Conditions: ovarian cancer, ovarian granulosa cell tumor, ovarian granulosa-stromal tumor
  • Phase: II
  • Trial ID: NCT05348356
  • Protocol ID: 22-277

Enrolling

Genetic Testing for Breast, Ovarian, Pancreatic and Prostate Cancers – GeneBOPP

Trial Description: This study is evaluating the effect of two pre-test education methods on participants interested in genetic testing for hereditary cancer risk.

  • Conditions: breast cancer, metastatic prostate cancer, ovarian cancer, pancreatic cancer
  • Phase: Not Applicable
  • Trial ID: NCT04330716
  • Protocol ID: 19-652

Not Enrolling

An open-label phase 1b study to determine the maximum tolerated and/or recommended phase 2 dose of the ATR inhibitor elimusertib (BAY 1895344) in combination with PARP inhibitor niraparib, in participants with recurrent advanced solid tumors and ovarian cancer

Trial Description: The purpose of the study is to test how well patients with advanced solid tumors and ovarian cancer respond to treatment with elimusertib in combination with niraparib. In addition researchers want to find for patients the optimal dose of elimusertib in combination with niraparib, how the drug is tolerated and the way the body absorbs, distributes and discharges the drug. The study medication elimusertib works by blocking a substance produced by the body (ATR Kinase) which is important for the growth of tumor cells. Niraparib works by blocking a substance produced by the body (PARP enzymes) in a way that tumor cells can be killed, or made more susceptible to chemotherapy.

  • Conditions: advanced solid tumors (excluding prostate cancer), ovarian cancer
  • Phase: I/II
  • Trial ID: NCT04267939
  • Protocol ID: 19-810

Not Enrolling

A PHASE I/II, OPEN-LABEL, MULTICENTER, DOSE ESCALATION STUDY OF MRNA-2416, A LIPID NANOPARTICLE ENCAPSULATED MRNA ENCODING HUMAN OX40L, FOR INTRATUMORAL INJECTION TO PATIENTS WITH ADVANCED MALIGNANCIES

Trial Description: This clinical study will assess the safety and tolerability of escalating doses of mRNA-2416 alone and in combination with administered fixed doses of durvalumab in participants with relapsed/refractory solid tumor malignancies or lymphoma, as well as the objective response rate (ORR) of mRNA-2416 alone or in combination with durvalumab in ovarian cancer based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The applicable dose of mRNA-2416 will be injected directly into the participant's tumor (intratumoral) and the applicable dose of durvalumab will be administered intravenously.

  • Conditions: ovarian cancer, relapsed/refractory solid tumor malignancies or lymphoma
  • Phase: I
  • Trial ID: NCT03323398
  • Protocol ID: 17-334

Enrolling

Comprehensive Outcomes for After Cancer Health (COACH): The Feasibility and Impact of an mHealth Augmented Coaching Program for Self-Management in Cancer Survivors

Trial Description: This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 500 individuals with diverse cancer diagnoses will be enrolled across up to 5 clinical sites to participate in a randomized wait-list control study. Those in the intervention group will receive 6 months of digital coaching up front followed by 6 months of ongoing monitoring via patient reported and clinical outcomes, as well as wearable data. Those in the control group

  • Conditions: breast cancer, gastric cancer, lung cancer, ovarian cancer, survivorship
  • Phase: Feasibility / Pilot
  • Trial ID: NCT05349227
  • Protocol ID: 21-737

Not Enrolling

A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination with Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin, in Adults with Folate Receptor Alpha Positive Advanced Epith

Trial Description: This study comprises a Dose Escalation phase followed by a Dose Expansion phase. Dose Escalation part of the study will assess the safety and tolerability and determine the maximum tolerated dose (MTD) as the recommended Phase 2 (RP2D) dose for each regimen. Participants will be assigned to one of the 4 regimens in Dose Escalation phase: Regimen A: mirvetuximab soravtansine administered with bevacizumab; Regimen B: mirvetuximab soravtansine administered with carboplatin; Regimen C: mirvetuximab soravtansine administered with pegylated liposomal doxorubicin; or Regimen D

  • Conditions: epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer
  • Phase: I
  • Trial ID: NCT02606305
  • Protocol ID: 15-505

Enrolling

A PHASE 1b STUDY OF ZN-c3 IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH PLATINUM -RESISTANT OVARIAN, PERITONEAL, OR FALLOPIAN TUBE CANCER

Trial Description: This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs

  • Conditions: epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, solid tumor
  • Phase: I
  • Trial ID: NCT04516447
  • Protocol ID: 21-580

Not Enrolling

A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination with Other Anticancer Agents in Patients with a Solid Tumor

Trial Description: This is an open label, Phase 1b/2 study with multiple treatment arms evaluating the safety, tolerability, PK, and preliminary efficacy of rucaparib in combination with a second anticancer therapy in patients with an advanced/metastatic solid malignancy (Phase 1b), followed by evaluation of the combination in one or more specific patient populations in an expansion phase (Phase 2 cohorts

  • Conditions: ovarian cancer, solid tumor, triple-negative breast cancer, urothelial carcinoma
  • Phase: I/II
  • Trial ID: NCT03992131
  • Protocol ID: 19-168

Enrolling

A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors

Trial Description: This is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical efficacy of INCB106385 when given as monotherapy or in combination with INCMGA00012 in participants with selected CD8 T-cell-positive advanced solid tumors including SCCHN, NSCLC, ovarian cancer, CRPC, TNBC, bladder cancer, and specified GI malignancies (defined as CRC, gastric/GEJ cancer, HCC, PDAC, or SCAC)

  • Conditions: bladder cancer, castration resistant prostate cancer, colorectal cancer, gastric/ gastroesophageal junction, hepatocellular carcinoma, non small cell lung cancer, ovarian cancer, pancreatic ductal adenocarcinoma, squamous carcinoma of the anal canal, squamous cell carcinoma of head and neck, triple negative breast cancer
  • Phase: I
  • Trial ID: NCT04580485
  • Protocol ID: 21-076

Not Enrolling

A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced Solid Tumors

Trial Description: This is an open-label, multicenter Phase 1b/2 study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of ARRY-382 in combination with pembrolizumab in adult patients with selected advanced solid tumors (Part A/Phase 1b); and to estimate the efficacy of the combination in three separate cohorts: 1) patients with advanced solid tumors that have progressed on prior PD-1/PD-L1inhibitors, 2) patients with platinum-resistant ovarian cancer and 3) patients with pancreatic ductal adenocarcinoma (Phase 2).

  • Conditions: advanced solid tumors
  • Phase: I/II
  • Trial ID: NCT02880371
  • Protocol ID: 16-399

Not Enrolling

A Phase 2, Randomized, Open-label, 3-arm Study of Relacorilant in Combination with Nab-Paclitaxel for Patients with Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Trial Description: This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel alone.

  • Conditions: recurrent fallopian tube carcinoma, recurrent ovarian cancer, recurrent primary peritoneal carcinoma
  • Phase: II
  • Trial ID: NCT03776812
  • Protocol ID: 19-210

Enrolling

EFFORT: EFFicacy Of ceralasertib (AZD6738) and adavosertib (AZD1775) in parp ResisTance; A Randomized 3-arm non-comparative Phase 2 Study of adavosertib alone, adavosertib plus olaparib, and ceralasertib plus olaparib in Women with Ovarian Cancer who have progressed during PARP inhibition

Trial Description: This phase II trial studies how well adavosertib with or without olaparib work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent). Adavosertib and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

  • Conditions: recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma
  • Phase: II
  • Trial ID: NCT03579316
  • Protocol ID: 19-059

Not Enrolling

Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expression

Trial Description: This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to: - Find the recommended dose of BT5528 that can be given safely to participants alone and in combination with nivolumab - Learn more about the side effects of BT5528 - Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cancer (NSCLC), triple-negative breast cancer, head and neck cancer (HNSCC), and gastric/upper gastrointestinal cancer. - Learn more about BT5528 therapy alone and in combination with nivolumab.

  • Conditions: advanced solid tumor historically known for high epha2 expression, gastric/upper gastrointestinal cancer, head and neck cancer, non-small cell lung cancer, ovarian cancer, triple negative breast cancer, urothelial cancer
  • Phase: I/II
  • Trial ID: NCT04180371
  • Protocol ID: 19-885

Not Enrolling

SIGNAL: Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care

Trial Description: This research study is testing the use of a smartphone app to identify clinically meaningful changes in the behaviors of patients' with gynecological cancers by using passively collected smartphone data.

  • Conditions: cervical cancer, fallopian tube cancer, gynecologic cancer, ovarian cancer, primary peritoneal carcinoma, uterine cancer
  • Phase: Feasibility / Pilot
  • Trial ID: NCT04368130
  • Protocol ID: 20-246

Not Enrolling

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of ceralasertib in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid M

Trial Description: This is a modular, phase I/ phase 1 b, open-label, multicentre study of ceralasertib administered orally in combination with cytotoxic chemotherapy regimens and/or novel anti-cancer agents, to patients with advanced malignancies. The study design allows an investigation of optimal combination dose of ceralasertib with other anti-cancer treatments, with intensive safety monitoring to ensure the safety of the patients. The initial combination to be investigated is ceralasertib with carboplatin. The second combination to be investigated is ceralasertib with Olaparib. The third combination to be investigated is ceralasertib with durvalumab

  • Conditions: adv solid malig - h&n scc atm pro / def nsclc gastric breast and ovarian cancer
  • Phase: I
  • Trial ID: NCT02264678
  • Protocol ID: 18-342

Not Enrolling

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (enapotamab vedotin- HuMax-AXL-ADC) in patients with solid tumors

Trial Description: The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors

  • Conditions: cervical cancer, endometrial cancer, melanoma, non small cell lung cancer, ovarian cancer, sarcoma, thyroid cancer
  • Phase: I/II
  • Trial ID: NCT02988817
  • Protocol ID: 18-183